Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern.
Health sciences
immune response
immunology
virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
16 Sep 2022
16 Sep 2022
Historique:
received:
05
04
2022
revised:
25
07
2022
accepted:
10
08
2022
pubmed:
23
8
2022
medline:
23
8
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
The global pandemic caused by SARS-CoV-2 is a major public health problem. Virus entry occurs via binding to ACE2. Five SARS-CoV-2 variants of concern (VOCs) were reported so far, all having immune escape characteristics. Infection with the current VOC Omicron was noticed in immunized and recovered individuals; therefore, the development of new treatments against VOC infections is urgently needed. Most approved mAbs treatments against SARS-CoV-2 are directed against the spike protein of the original virus and are therefore inefficient against Omicron. Here, we report on the generation of hACE2.16, an anti-ACE2 antibody that recognizes and blocks ACE2-RBD binding without affecting ACE2 enzymatic activity. We demonstrate that hACE2.16 binding to ACE2 does not affect its surface expression and that hACE2.16 blocks infection and virus production of various VOCs including Omicron BA.1 and BA.2. hACE2.16 might, therefore, be an efficient treatment against all VOCs, the current and probably also future ones.
Identifiants
pubmed: 35992307
doi: 10.1016/j.isci.2022.104935
pii: S2589-0042(22)01207-X
pmc: PMC9375641
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104935Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
A patent application has been submitted by Yissum, the Hebrew University Tech Transfer Company, based on these results.
Références
Cell Rep. 2022 May 17;39(7):110812
pubmed: 35568025
PLoS Pathog. 2021 Dec 20;17(12):e1010175
pubmed: 34929007
Respir Physiol Neurobiol. 2021 Jan;283:103548
pubmed: 32956843
J Clin Med. 2021 Aug 29;10(17):
pubmed: 34501332
Science. 1996 Apr 12;272(5259):263-7
pubmed: 8602510
Lancet Infect Dis. 2022 Jun;22(6):813-820
pubmed: 35305699
iScience. 2020 Nov 20;23(11):101744
pubmed: 33134888
Cell Mol Life Sci. 2021 Jan;78(2):531-544
pubmed: 32780149
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Lancet Infect Dis. 2022 Jul;22(7):942-943
pubmed: 35690075
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
Signal Transduct Target Ther. 2022 Feb 9;7(1):43
pubmed: 35140198
Commun Biol. 2021 Oct 13;4(1):1196
pubmed: 34645933
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Cell. 2022 Jun 9;185(12):2103-2115.e19
pubmed: 35568035
Signal Transduct Target Ther. 2021 Aug 25;6(1):315
pubmed: 34433803
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
J Mol Biol. 2021 Jul 23;433(15):167058
pubmed: 34023401
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Nat Rev Genet. 2021 Dec;22(12):757-773
pubmed: 34535792
Biochem Biophys Res Commun. 2022 Jan 29;590:34-41
pubmed: 34968782
Curr Protoc Protein Sci. 2001 May;Chapter 6:Unit 6.6
pubmed: 18429193
Emerg Microbes Infect. 2022 Dec;11(1):277-283
pubmed: 34951565
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Cell Host Microbe. 2021 May 12;29(5):747-751.e4
pubmed: 33887205
Hypertension. 2016 Aug;68(2):365-77
pubmed: 27217402
MAbs. 2011 Sep-Oct;3(5):415-6
pubmed: 21785279
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826
pubmed: 34915551
N Engl J Med. 2021 Oct 7;385(15):1382-1392
pubmed: 34260849
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Autoimmun. 2022 Jan;126:102779
pubmed: 34915422
Trends Pharmacol Sci. 2020 Nov;41(11):815-829
pubmed: 32829936
Life Sci Alliance. 2020 Jul 23;3(9):
pubmed: 32703818
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855